Protocol No.: D5290C00005

Title
A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in High-risk Children (MEDLEY)
Principal Investigator
Polak, Mark
Phase
II/III
Age Group
Children
Applicable Disease Site
Other
Participating Institution
Health Sciences Center
Contact
Joseph Scattaregia
Clinical Research Coord
Phone: +1 304-293-9512

View on ClinicalTrials.gov